News Releases

News Releases

November 29, 2021

NervGen Pharma Corp. Closes Non-Brokered Private Placement

November 18, 2021

NervGen Pharma Reports Third Quarter 2021 Results

November 12, 2021

NervGen Pharma Completes $9.2 Million Bought Deal Financing

November 5, 2021

NervGen Pharma Announces Increase to Bought Deal Financing to $8.0 Million

November 4, 2021

NervGen Pharma Announces $5,000,000 Bought Deal Financing

November 4, 2021

NervGen Presents Additional Phase 1 Clinical Trial Data for NVG-291 at Neuroscience 2021 / Safety Review Committee Provides Recommendation to Proceed to Multiple Ascending Dose Portion of the Trial

October 27, 2021

NervGen Pharma Announces Spinal Cord Injury Clinical Advisory Board

October 18, 2021

NervGen Presents Interim Phase 1 Clinical Trial Data for NVG-291 at the American Neurological Association 146th Annual Meeting / NVG-291 Demonstrated to be Well Tolerated Along with a Favorable Pharmacokinetic Profile

October 4, 2021

U.S. Senate Defense Bill Includes NervGen Supported Language on Promise of Brain Plasticity Therapeutics for Traumatic Brain Injury

September 27, 2021

NervGen Pharma Partners with Imeka to Use Novel Neuroimaging Technology in Clinical Trials

Articles

The controversy around falsified Alzheimer’s research

October 24, 2022

NervGen is featured in Health Europa.

Peptide Promotes Nervous System Repair in Stroke Animal Models

July 29, 2022

Read about NervGen in this article in Genetic Engineering and Biotechnology News

With Some Help, Small Canadian Biotech Could Challenge Roche's Hold in Stroke Treatment

July 29, 2022

Read about NervGen and our preclinical results in stroke in this article in BioSpace

Media

Grit Daily Startup

July 4, 2022

Paul Brennan, NervGen President & CEO is interviewed by Stebastian Rusk of the Grit Daily Startup podcast.

Midas Letter Live

February 11, 2022

Interview with Paul Brennan, NervGen President & CEO (Interview at 29:22 in video)

Big Business Show

June 30, 2021

Bob Sullivan, Big Business Show, interviews Paul Brennan.

NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen is evaluating a new discovery lead, NVG-300, in a preclinical model of ischemic stroke and confirmatory SCI study.

Contact

112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4

Phone: (778) 731-1711
Email: [email protected]

Subscribe for Updates